Abstract
In relapsing-remitting multiple sclerosis (RRMS), smoking is a known risk factor of disease development and disability progression. However, little is known about the impact of smoking on the efficacy of fingolimod. Here we studied the relationship between smoking and relapses in patients with RRMS under fingolimod treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
